source Post navigation ACC 25: semaglutide improves function in PAD patients with T2D in STRIDE study – Clinical Trials Arena Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial – Nature